United States Adult Vaccine Market Report by Disease wise – Adult Vaccines Market, Disease wise – Numbers of Vaccinated Adults, States and Company Analysis, 2026-2034

United States Adult Vaccine Market Size and Forecast 2026-2034

United States Adult Vaccine Market is expected to reach US$ 11.77 Billion by 2034 from US$ 6.95 Billion in 2025, with a CAGR of 6.03% from 2026 to 2034. An aging U.S. population, rising chronic disease prevalence, and increasing awareness of vaccine-preventable complications are expanding demand for influenza, pneumococcal, shingles, RSV, hepatitis, and other adult vaccines across healthcare settings.

United States Adult Vaccine Industry Overview

The United States adult vaccine industry represents a broad preventive-healthcare segment covering routine, age-based, risk-based, occupational, travel-related, and condition-specific immunization. The market encompasses vaccines against influenza, pneumococcal disease, shingles, RSV, hepatitis, HPV, tetanus, meningococcal disease, COVID-19 and other vaccine-preventable conditions. CDC recommendations increasingly differentiate vaccination requirements according to age, underlying health conditions, pregnancy, occupation, exposure risk and individual circumstances. Adults are generally advised to receive annual influenza vaccination, periodic Tdap or Td boosters, and age- or risk-appropriate vaccines such as shingles, pneumococcal and RSV products.

Demographic aging is an important structural factor supporting demand. Older adults face greater risks from respiratory infections and complications, encouraging vaccination against influenza, pneumococcal disease, shingles and RSV. The introduction and expansion of RSV vaccination recommendations have further diversified the adult vaccine landscape. In June 2025, ACIP recommended a single RSV vaccine dose for adults aged 50–59 years who have increased risk of severe RSV disease, extending protection beyond older age groups. CDC's schedule also recommends RSV vaccination for adults aged 75 years and older and certain adults aged 50–74 years.

Despite extensive vaccine availability, adult immunization uptake remains below potential levels for several recommended vaccines. CDC's 2024 National Health Interview Survey assessment reported low coverage for most recommended adult vaccines, while shingles vaccination among adults aged 50 years and older continued to improve. Influenza remains particularly important because vaccination is recommended annually; nevertheless, coverage among U.S. adults declined to 41.9% during the 2024–25 season. These gaps create opportunities for pharmacies, physician offices, hospitals, employers and public-health programs to increase vaccination through reminders, convenient administration and stronger patient education.

Recent Developments in United States Adult Vaccine Market

• In June 2025, ACIP recommended a single RSV vaccine dose for adults aged 50–59 years with increased risk of severe RSV disease, broadening the addressable adult population beyond older adults.

Growth Drivers for the United States Adult Vaccine Market

Demographic Aging and Respiratory Disease Prevention

The aging U.S. population is creating sustained demand for vaccines designed to prevent severe infectious diseases among older adults. Age is associated with greater susceptibility to complications from influenza, pneumococcal disease, shingles and respiratory syncytial virus, making adult immunization increasingly important within preventive healthcare. CDC recommendations specifically emphasize vaccination according to age and risk, with shingles vaccination recommended for adults in specified age groups, pneumococcal vaccination for recommended adults, annual influenza vaccination and RSV vaccination for older or higher-risk populations. The expansion of RSV recommendations to certain adults aged 50–59 years with increased risk further broadens the market. As healthcare providers increasingly integrate vaccination into routine chronic-disease management and annual wellness visits, opportunities for vaccine administration are expanding. Pharmacies and other accessible vaccination locations also help reach older adults, supporting recurring demand and strengthening the preventive-care role of adult vaccines.

Persistent Immunization Gaps and Catch-Up Opportunities

Low vaccination coverage across several adult populations represents an important growth opportunity for the U.S. vaccine industry. CDC's 2024 National Health Interview Survey found that coverage remained low for most recommended adult vaccines, while disparities were observed across demographic groups. Such gaps indicate that market expansion does not depend exclusively on population growth or the introduction of new products; increasing vaccination among eligible adults can itself generate substantial incremental demand. Healthcare providers, pharmacies, employers and public-health organizations can improve uptake through reminders, electronic health-record prompts, convenient scheduling and vaccination during routine consultations. Influenza provides a particularly significant opportunity because it requires annual vaccination, creating recurring demand. Similarly, increasing awareness of shingles, pneumococcal, hepatitis and HPV prevention can support additional vaccine administration among eligible populations. Greater emphasis on preventive care and closing immunization disparities therefore provides a durable demand foundation for adult vaccines.

Expanding Vaccine Portfolio and Personalized Recommendations

The adult vaccine industry is benefiting from a broader and increasingly differentiated portfolio designed around age, health status and individual risk. Modern recommendations include multiple influenza vaccine technologies, recombinant and conjugate products, RSV vaccines, shingles vaccination, pneumococcal conjugate vaccines, hepatitis vaccines and HPV immunization. CDC's adult schedule distinguishes between universal recommendations, risk-based vaccination and shared clinical decision-making, enabling providers to tailor immunization strategies rather than applying a single approach to every adult. The introduction of newer products and expanded eligibility can therefore increase the number of adults considered for vaccination. RSV is a prominent example, with recommendations covering older adults and selected younger high-risk populations. HPV vaccination also creates an additional opportunity among certain adults aged 27–45 years through shared clinical decision-making. This increasingly diversified portfolio supports market development while encouraging healthcare systems to integrate immunization into personalized preventive-care pathways.

Challenges in the United States Adult Vaccine Market

Uneven Uptake and Vaccine Hesitancy

Adult vaccine demand remains constrained by inconsistent uptake, uncertainty about recommendations and vaccine hesitancy. Unlike childhood immunization, adult vaccination often depends on individuals recognizing their eligibility and actively seeking preventive care. CDC data show that coverage remains low for several recommended adult vaccines, while influenza coverage declined during the 2024–25 season. Misunderstanding about vaccine benefits, concerns about adverse effects, competing health priorities and limited awareness can reduce acceptance. The complexity of adult recommendations can also create confusion because vaccination requirements differ according to age, medical conditions, pregnancy, occupation and other risk factors. Healthcare providers therefore play an important role in identifying missed vaccinations and communicating individualized benefits. Expanding reminder systems, pharmacy-based vaccination, workplace programs and patient education can help address these barriers, but improving uptake remains a continuing challenge for manufacturers, providers and public-health agencies.

Access, Affordability and Delivery Complexity

The adult vaccine market faces operational challenges related to access, affordability, reimbursement and administration. Adults receive vaccines through multiple channels, including physician practices, pharmacies, hospitals, clinics and workplace programs, creating a fragmented delivery environment. Some individuals may encounter difficulties identifying recommended vaccines, scheduling appointments or understanding insurance coverage. Complex dosing schedules can create additional barriers when multiple visits are required. Manufacturers and healthcare providers must also manage seasonal demand, especially for influenza vaccines, while maintaining reliable supply and distribution. Differences in vaccination rates between demographic groups further indicate that access is not uniform across the country. CDC has identified disparities in adult vaccination coverage across racial and ethnic populations. Addressing these challenges requires coordinated public-health outreach, provider recommendations, convenient administration locations and effective reimbursement mechanisms. Without such improvements, vaccine availability alone may not translate into higher immunization rates or sustained market penetration.

California: Large Population Meets Preventive-Health Demand

California represents a significant adult vaccine market because of its large and diverse population, extensive healthcare infrastructure and strong emphasis on preventive health. Demand spans seasonal influenza, COVID-19, pneumococcal, shingles, HPV, hepatitis and other recommended adult vaccines. The state's substantial older-adult population supports demand for age-related immunizations, while its diverse demographic composition creates opportunities for targeted outreach and improved vaccination equity. California's extensive network of hospitals, physician practices, community health organizations and pharmacies provides multiple administration channels. Adult immunization programs can also benefit from integrating vaccination into routine primary care, chronic-disease management and pharmacy services. CDC recommendations covering age and risk-based vaccination provide a framework for providers to identify eligible adults. Growth opportunities are particularly associated with improving coverage among under-vaccinated populations and increasing awareness of vaccines beyond influenza and COVID-19.

Texas: High Population Base Supports Broad Vaccine Demand

Texas offers substantial potential for adult vaccine demand due to its large population, geographically dispersed communities and broad healthcare delivery network. The market encompasses routine adult immunization as well as vaccines associated with age, occupational exposure, travel and underlying health conditions. Influenza remains a recurring opportunity because adults are recommended to receive vaccination annually, while hepatitis, pneumococcal, shingles, HPV and RSV vaccines address additional population segments. The state's geographic diversity creates a need for accessible vaccination through pharmacies, primary-care providers, community clinics and public-health facilities. Increasing awareness among younger adults and higher-risk populations can support greater adoption of vaccines beyond seasonal influenza. Texas also provides opportunities for employer-based vaccination and targeted outreach programs, particularly where healthcare access is uneven. As providers increasingly incorporate preventive services into routine care, the state's large addressable population can support continued expansion of adult immunization activity.

New York: Dense Healthcare Infrastructure Strengthens Distribution

New York represents an important adult vaccine market supported by dense healthcare infrastructure, a large urban population and extensive provider and pharmacy networks. Adult immunization demand includes influenza, pneumococcal, shingles, HPV, hepatitis, RSV and other vaccines recommended according to age and risk. New York's health authorities emphasize that adult vaccination requirements vary according to age, health conditions, lifestyle, risk factors and travel plans, reinforcing the importance of individualized vaccination assessment. The concentration of hospitals, primary-care practices, pharmacies and public-health services creates multiple opportunities to administer vaccines. Large metropolitan populations also provide opportunities for digital reminders, workplace programs and pharmacy-based vaccination campaigns. At the same time, improving coverage among populations with lower uptake remains important. Continued integration of immunization with routine healthcare visits and preventive services can strengthen vaccine utilization across the state while supporting demand for established and newer adult vaccine products.

Florida: Older Population Creates Strong Preventive-Care Potential

Florida has strong potential for adult vaccine demand because of its comparatively older population and extensive healthcare and pharmacy infrastructure. Older adults represent an important target group for shingles, pneumococcal, influenza and RSV vaccination because the risk of severe outcomes generally increases with age. Seasonal population movements and a large retiree community can also create recurring demand for accessible vaccination services. Pharmacies, primary-care providers, hospitals and community health centers provide multiple administration channels, enabling vaccines to be delivered outside traditional physician settings. Influenza vaccination is particularly relevant because CDC recommends annual immunization for adults, while RSV and pneumococcal recommendations create additional opportunities among eligible older and higher-risk populations. Market development will depend on improving awareness, maintaining convenient access and encouraging adults to receive multiple age-appropriate vaccines during routine healthcare encounters. These factors position Florida as an important market for adult preventive immunization.

Influenza: Recurring Seasonal Demand Anchors the Market

Influenza represents one of the most established segments of the U.S. adult vaccine industry because vaccination is recommended annually for adults without contraindications. The recurring nature of seasonal immunization creates predictable replacement demand and requires manufacturers to continuously update formulations according to circulating influenza strains. CDC reported adult influenza vaccination coverage of 41.9% during the 2024–25 season, representing a decline from 44.9% in 2023–24. This relatively low coverage also indicates substantial room for market expansion through improved uptake. Product differentiation includes egg-based, cell-culture, recombinant and high-dose or adjuvanted formulations designed for different populations. FDA's annual strain-selection process supports alignment between vaccine composition and surveillance findings. For 2025–26, FDA reviewed U.S. and global surveillance data before issuing strain recommendations, while updated approvals continue supporting seasonal supply.

HPV: Cancer Prevention Broadens Adult Vaccine Relevance

The HPV vaccine segment is primarily associated with cancer prevention and creates an important bridge between vaccination and long-term disease prevention. CDC recommends routine HPV vaccination during adolescence and catch-up vaccination through age 26 for people who were not adequately vaccinated earlier. For certain adults aged 27–45 years, vaccination can be considered through shared clinical decision-making rather than routine universal recommendation. HPV vaccination prevents new infections and can reduce the risk of HPV-associated cancers, including cervical cancer and several other cancers. Adult demand is therefore influenced by awareness of cancer prevention, provider recommendations and individual exposure risk. However, uptake among adults beyond the routine vaccination age remains more selective because many have already been exposed to HPV. The segment's long-term opportunity lies in improving completion of adolescent and young-adult vaccination while identifying adults who could benefit from shared clinical decision-making.

Hepatitis: Risk-Based Immunization Supports Multiple Adult Segments

Hepatitis vaccination encompasses important adult-prevention opportunities through hepatitis A and hepatitis B immunization. Hepatitis B vaccination is routinely recommended for adults aged 19–59 years, while adults aged 60 years and older may receive vaccination when risk factors are present or through individual clinical assessment. Hepatitis A vaccination is recommended according to specific risk factors, travel, medical circumstances and other indications. The segment therefore extends across younger adults, healthcare and occupational populations, travelers and people with particular exposure risks. Combination hepatitis A and B vaccines can also support convenient immunization for appropriate populations. Market expansion depends heavily on healthcare-provider identification of eligible individuals because hepatitis vaccination is often less visible to consumers than annual influenza vaccination. Greater screening, preventive counseling, travel medicine and integration with routine primary care can increase opportunities for adult hepatitis vaccine administration.

Market Segmentations

Disease wise – Adult Vaccines Market

• Influenza
• Cervical Cancer (HPV)
• Zoster (Shingles)
• MMR (Measles, Mumps, and Rubella Vaccine)
• Pneumococcal
• Meningococcal
• Hepatitis
• TdaP
• Travel and Miscellaneous
• Varicella

Disease wise – Numbers of Vaccinated Adults

• Influenza
• Cervical Cancer (HPV)
• Zoster (Shingles)
• MMR
• Pneumococcal
• Meningococcal
• Hepatitis
• TdaP
• Varicella

States

• California
• Texas
• New York
• Florida
• Illinois
• Pennsylvania
• Ohio
• Georgia
• New Jersey
• Washington
• North Carolina
• Massachusetts
• Virginia
• Michigan
• Maryland
• Colorado
• Tennessee
• Indiana
• Arizona
• Minnesota
• Wisconsin
• Missouri
• Connecticut
• South Carolina
• Oregon
• Louisiana
• Alabama
• Kentucky
• Rest of United States

All Key Players have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Key Players Analysis

• GlaxoSmithKline, plc.’s Vaccines Sales
• AstraZeneca plc Vaccines Sales
• Sanofi Pasteur’s Vaccines Sales
• Pfizer, Inc.’s Vaccines Sales
• CSL Limited sales

Report Details: